ArticleNature2013
Staphylococcus δ-toxin induces allergic skin disease by activating mast cells.
Article in Nature, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03052348 (A Multicentre Study Evaluating the Efficacy of Combining Topical Antibiotic/Steroid/Moisturizer Therapy Compared to Standard of Care in the Treatment of Severe Atopic Dermatitis, a Phase II Randomized, Clinical Trial), which is not on this map. Cited by 294 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicentre Study Evaluating the Efficacy of Combining Topical Antibiotic/Steroid/Moisturizer Therapy Compared to Standard of Care in the Treatment of Severe Atopic Dermatitis, a Phase II Randomized, Clinical Trial
Who cites it
294 citing papers in PubMed, 533 citations in OpenAlex.
- Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.Frontiers in immunology · 2025Trial
- Topical niclosamide (ATx201) reduces Staphylococcus aureus colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double-blind, placebo-controlled Phase 2 trial.Clinical and translational medicine · 2022Trial
- Prospective, comparative clinical pilot study of cold atmospheric plasma device in the treatment of atopic dermatitis.Scientific reports · 2021Trial
- Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial.Nature medicine · 2021Trial
- The Skin Microbiome of Patients With Atopic Dermatitis Normalizes Gradually During Treatment.Frontiers in cellular and infection microbiology · 2021Trial
- Mast Cells in Host Defense Against Cutaneous Staphylococcus aureus Infection.Immunology and cell biology · 2026Review
- The potential effects, mechanisms and translational perspectives of natural products in the treatment of atopic dermatitis.Chinese medicine · 2026Review
- Berberine Inhibits Eczematous SkinInternational journal of molecular sciences · 2026Article
- Innate host defense lysozyme may help controlMicrobiology spectrum · 2026Article
- Immunopathogenesis of itch: an integrative framework for chronic pruritus.JID innovations : skin science from molecules to population health · 2026Review
- Antibacterial activity of glycerol monolaurate formulated in petrolatum.Microbiology spectrum · 2026Article
- Exploring Cyclo (-Gly-Pro) for inflammation modulation in atopic dermatitis: a study on streptococcal postbiotics.Genes & genomics · 2026Article
- Itching to know: the Microbiome, Allergic Disease, and Antimicrobial Chemicals.Current environmental health reports · 2026Review
- Atopic march protocol involving sequential skin and lung inflammation elicited by epicutaneous Staphylococcus aureus and allergen exposure.STAR protocols · 2026Article
- Whole genome sequences of novelMicrobiology resource announcements · 2026Article
- Dysbiosis in the Pathogenesis of Atopic Dermatitis.The Journal of dermatology · 2026Review
- Washed microbiota transplantation relieves atopic dermatitis via gut-skin microbiome rebalancing.BMC microbiology · 2026Article
- Microbiome dysbiosis and therapeutic restoration in atopic dermatitis.Frontiers in cellular and infection microbiology · 2026Review
- DnaK supports intracellular persistence of Staphylococcus xylosus and confers mechanical resilience to a human breast cancer cell line.PloS one · 2026Article
- The nasal-oral microbiome axis in allergic rhinitis: environmental triggers, microbial dysbiosis, and immune dysregulation.Frontiers in allergy · 2026Review
234 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 2 countries.
Funding
Abstract
Atopic dermatitis is a chronic inflammatory skin disease that affects 15-30% of children and approximately 5% of adults in industrialized countries. Although the pathogenesis of atopic dermatitis is not fully understood, the disease is mediated by an abnormal immunoglobulin-E immune response in the setting of skin barrier dysfunction. Mast cells contribute to immunoglobulin-E-mediated allergic disorders including atopic dermatitis. Upon activation, mast cells release their membrane-bound cytosolic granules leading to the release of several molecules that are important in the pathogenesis of atopic dermatitis and host defence. More than 90% of patients with atopic dermatitis are colonized with Staphylococcus aureus in the lesional skin whereas most healthy individuals do not harbour the pathogen. Several staphylococcal exotoxins can act as superantigens and/or antigens in models of atopic dermatitis. However, the role of these staphylococcal exotoxins in disease pathogenesis remains unclear. Here we report that culture supernatants of S. aureus contain potent mast-cell degranulation activity. Biochemical analysis identified δ-toxin as the mast cell degranulation-inducing factor produced by S. aureus. Mast cell degranulation induced by δ-toxin depended on phosphoinositide 3-kinase and calcium (Ca(2+)) influx; however, unlike that mediated by immunoglobulin-E crosslinking, it did not require the spleen tyrosine kinase. In addition, immunoglobulin-E enhanced δ-toxin-induced mast cell degranulation in the absence of antigen. Furthermore, S. aureus isolates recovered from patients with atopic dermatitis produced large amounts of δ-toxin. Skin colonization with S. aureus, but not a mutant deficient in δ-toxin, promoted immunoglobulin-E and interleukin-4 production, as well as inflammatory skin disease. Furthermore, enhancement of immunoglobulin-E production and dermatitis by δ-toxin was abrogated in Kit(W-sh/W-sh) mast-cell-deficient mice and restored by mast cell reconstitution. These studies identify δ-toxin as a potent inducer of mast cell degranulation and suggest a mechanistic link between S. aureus colonization and allergic skin disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.